Vericel Corporation (VCEL): Price and Financial Metrics


Vericel Corporation (VCEL): $26.88

-1.84 (-6.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VCEL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VCEL POWR Grades


  • Quality is the dimension where VCEL ranks best; there it ranks ahead of 74.38% of US stocks.
  • The strongest trend for VCEL is in Momentum, which has been heading down over the past 179 days.
  • VCEL's current lowest rank is in the Sentiment metric (where it is better than 11.47% of US stocks).

VCEL Stock Summary

  • The price/operating cash flow metric for Vericel Corp is higher than 92.14% of stocks in our set with a positive cash flow.
  • With a price/sales ratio of 11.9, Vericel Corp has a higher such ratio than 87.67% of stocks in our set.
  • Over the past twelve months, VCEL has reported earnings growth of -348.46%, putting it ahead of merely 5.72% of US stocks in our set.
  • Stocks that are quantitatively similar to VCEL, based on their financial statements, market capitalization, and price volatility, are BSGM, DRIO, DKNG, EGHT, and UCL.
  • VCEL's SEC filings can be seen here. And to visit Vericel Corp's official web site, go to vcel.com.

VCEL Valuation Summary

  • In comparison to the median Healthcare stock, VCEL's price/sales ratio is 47.14% higher, now standing at 16.7.
  • VCEL's EV/EBIT ratio has moved up 283.1 over the prior 243 months.
  • VCEL's EV/EBIT ratio has moved up 283.1 over the prior 243 months.

Below are key valuation metrics over time for VCEL.

Stock Date P/S P/B P/E EV/EBIT
VCEL 2021-08-31 16.7 16.7 288.3 275.6
VCEL 2021-08-30 17.1 17.2 296.3 283.3
VCEL 2021-08-27 17.1 17.2 295.9 283.0
VCEL 2021-08-26 16.2 16.2 280.1 267.8
VCEL 2021-08-25 16.5 16.6 286.1 273.6
VCEL 2021-08-24 16.2 16.3 280.5 268.2

VCEL Growth Metrics

    The 4 year price growth rate now stands at 432.66%.
  • Its 3 year net cashflow from operations growth rate is now at 93.69%.
  • Its year over year net cashflow from operations growth rate is now at 966.54%.
Over the past 70 months, VCEL's revenue has gone up $101,757,000.

The table below shows VCEL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 156.184 29.04 -7.471
2021-09-30 153.822 29.826 0.214
2021-06-30 151.574 30.762 8.763
2021-03-31 132.069 22.972 4.28
2020-12-31 124.179 17.572 2.864
2020-09-30 118.34 9.385 0.145

VCEL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VCEL has a Quality Grade of C, ranking ahead of 72.89% of graded US stocks.
  • VCEL's asset turnover comes in at 0.761 -- ranking 35th of 682 Pharmaceutical Products stocks.
  • TCON, NMTR, and PTCT are the stocks whose asset turnover ratios are most correlated with VCEL.

The table below shows VCEL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.761 0.699 0.052
2021-03-31 0.732 0.685 0.031
2020-12-31 0.753 0.678 0.023
2020-09-30 0.779 0.671 0.001
2020-06-30 0.793 0.670 0.000
2020-03-31 0.866 0.683 -0.094

VCEL Price Target

For more insight on analysts targets of VCEL, see our VCEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $65.04 Average Broker Recommendation 1.29 (Strong Buy)

VCEL Stock Price Chart Interactive Chart >

Price chart for VCEL

VCEL Price/Volume Stats

Current price $26.88 52-week high $68.94
Prev. close $28.72 52-week low $25.11
Day low $26.21 Volume 558,500
Day high $28.08 Avg. volume 540,738
50-day MA $33.82 Dividend yield N/A
200-day MA $41.11 Market Cap 1.27B

Vericel Corporation (VCEL) Company Bio


Vericel Corporation focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company was founded in 1989 and is based in Cambridge, Massachusetts.


VCEL Latest News Stream


Event/Time News Detail
Loading, please wait...

VCEL Latest Social Stream


Loading social stream, please wait...

View Full VCEL Social Stream

Latest VCEL News From Around the Web

Below are the latest news stories about Vericel Corp that investors may wish to consider to help them evaluate VCEL as an investment opportunity.

Vericel Corporation (VCEL) CEO Nick Colangelo on Q4 2021 Results - Earnings Call Transcript

Vericel Corporation. (VCEL) Q4 2021 Earnings Conference Call February 24, 2022, 08:30 AM ET Company Participants Eric Burns - Head of Financial Planning and Analysis & Investors Relations Nick Colangelo - President & Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Danielle...

SA Transcripts on Seeking Alpha | February 24, 2022

Vericel Announces Appointment of Jonathan Siegal as Principal Accounting Officer

CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Board of Directors has appointed Jonathan Siegal as the Company’s Principal Accounting Officer, effective February 16, 2022. Mr. Siegal is currently serving as Vericel’s Vice President and Corporate Controller. Mr. Siegal joined Vericel in September 2021 with over 20 years of accounting and financial l

Yahoo | February 24, 2022

Vericel Corporation (VCEL) Q4 Earnings Miss Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -47.06% and 0.24%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Vericel Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Full-Year 2022 Financial Guidance

Full-Year 2021 Total Revenue Growth of 26% Full-Year 2022 Total Revenue Guidance of $178 to $189 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2021, and provided full-year 2022 financial guidance. Fourth Quarter 2

Yahoo | February 24, 2022

Vericel Q4 2021 Earnings Preview

Vericel (NASDAQ:VCEL) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is $0.14 (-44.0% Y/Y) and the consensus Revenue Estimate is $48.09M (+6.4% Y/Y). Over the last 2 years, VCEL has beaten EPS estimates 75% of the time and has beaten...

Seeking Alpha | February 23, 2022

Read More 'VCEL' Stories Here

VCEL Price Returns

1-mo -28.03%
3-mo -22.98%
6-mo -39.36%
1-year -48.04%
3-year 68.42%
5-year 914.34%
YTD -31.60%
2021 27.27%
2020 77.47%
2019 0.00%
2018 219.27%
2017 81.67%

Continue Researching VCEL

Here are a few links from around the web to help you further your research on Vericel Corp's stock as an investment opportunity:

Vericel Corp (VCEL) Stock Price | Nasdaq
Vericel Corp (VCEL) Stock Quote, History and News - Yahoo Finance
Vericel Corp (VCEL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8566 seconds.